1. Home
  2. REPL vs GDOT Comparison

REPL vs GDOT Comparison

Compare REPL & GDOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • GDOT
  • Stock Information
  • Founded
  • REPL 2015
  • GDOT 1999
  • Country
  • REPL United States
  • GDOT United States
  • Employees
  • REPL N/A
  • GDOT N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • GDOT Finance: Consumer Services
  • Sector
  • REPL Health Care
  • GDOT Finance
  • Exchange
  • REPL Nasdaq
  • GDOT Nasdaq
  • Market Cap
  • REPL 547.0M
  • GDOT 545.1M
  • IPO Year
  • REPL 2018
  • GDOT 2010
  • Fundamental
  • Price
  • REPL $5.56
  • GDOT $13.30
  • Analyst Decision
  • REPL Buy
  • GDOT Hold
  • Analyst Count
  • REPL 10
  • GDOT 3
  • Target Price
  • REPL $8.25
  • GDOT $11.00
  • AVG Volume (30 Days)
  • REPL 24.2M
  • GDOT 959.8K
  • Earning Date
  • REPL 08-07-2025
  • GDOT 08-11-2025
  • Dividend Yield
  • REPL N/A
  • GDOT N/A
  • EPS Growth
  • REPL N/A
  • GDOT N/A
  • EPS
  • REPL N/A
  • GDOT N/A
  • Revenue
  • REPL N/A
  • GDOT $1,922,023,000.00
  • Revenue This Year
  • REPL N/A
  • GDOT $22.44
  • Revenue Next Year
  • REPL $194.05
  • GDOT $12.64
  • P/E Ratio
  • REPL N/A
  • GDOT N/A
  • Revenue Growth
  • REPL N/A
  • GDOT 22.09
  • 52 Week Low
  • REPL $2.68
  • GDOT $6.13
  • 52 Week High
  • REPL $17.00
  • GDOT $14.27
  • Technical
  • Relative Strength Index (RSI)
  • REPL 44.05
  • GDOT 70.97
  • Support Level
  • REPL $4.49
  • GDOT $9.31
  • Resistance Level
  • REPL $6.39
  • GDOT $14.27
  • Average True Range (ATR)
  • REPL 0.77
  • GDOT 0.59
  • MACD
  • REPL 0.09
  • GDOT 0.43
  • Stochastic Oscillator
  • REPL 48.77
  • GDOT 80.44

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About GDOT Green Dot Corporation $0.001 par value

Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.

Share on Social Networks: